

# Vaishali Pharma Ltd.



**CORPORATE & REGISTERED OFFICE :**  
706-709, 7th Floor, Aravali Business Centre,  
R. C. Patel Road, Off. Sodawala Lane,  
Borivali (West), Mumbai-400 092.  
Tel.: +91-22-4217 1819  
E-mail : sales@vaishalipharma.com  
**CIN - L52310MH2008PLC181632**



Certification Partner Global  
ISO 9001 : 2015 Certified



GOVT. RECOGNIZED  
STAR EXPORT HOUSE

01<sup>st</sup> January, 2021

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051

**Stock Code: VAISHALI**

Dear Sir/Madam,

**SUB: UPDATION ON THE MAJOR BULK ORDER OF INR 160 MILLION FOR PPE KITS & COVID -19  
MEDICAL KITS**

We are very pleased to inform our shareholders that in relation with the Large bulk order worth INR 160 Million, the Company has fulfilled its Delivery with efficiency and in less timeframe, with this the Company has established a good reputation and is expecting many more orders for the same products in the Domestic as well as International Markets.

Please find enclosed herewith a copy of Press Release giving information about the same and many more.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,  
**For Vaishali Pharma Limited**

*Akshay Jharkhandi*  
Akshay Jharkhandi  
Company Secretary



**UPDATION ON THE MAJOR BULK ORDER OF INR 160 MILLION FOR PPE KITS & COVID -19 MEDICAL KITS**

**Mumbai, January 01, 2021:** Vaishali Pharma Limited (NSE:- VAISHALI), a Mumbai based Company, engaged in supply of pharmaceutical products to corporates, hospitals and retails stores in all SKUs required. Our products have made its grasp on the overseas market and getting an excellent feedback worldwide. The Company is showing consistent agility and innovation by meeting the needs of its customers in both Domestic and International markets.

The Company is pleased to inform our shareholders that in relation with the Large bulk order worth INR 160 Million, the Company has fulfilled its Delivery with efficiency and in less timeframe, with this the Company has established a good reputation and is expecting many more orders for the same products in the Domestic as well as International Markets in the near future. It is now the time for the Company to promote the same products in the International Markets which are under the stronghold of the Company.

In addition to the current exports of the surgical products, the Company has reached out more and more territories and has newly included **Fiji**, from where the Company has received orders for the exports of its Surgical Products.

Currently the Company is expecting more exports orders for its surgical products from the following countries:-



Angola



Georgia



Ghana



Kenya



Myanmar



Nigeria

In this Covid-19 Pandemic situation, and the health awareness in society, we are expecting much bigger orders in near future.

**Mr. Atul Arvind Vasani, Chairman and Managing Director of the Company** says that: *"In addition to the current export of the Companies Surgical Products to Angola, Georgia, Ghana, Kenya, Myanmar, Nigeria and our team has reached out more and more territories and has newly included Fiji for the exports of its Surgical Products.*

*Further, we are expecting more export orders from Domestic as well as International Markets in the near future."*

**ABOUT VAISHALI PHARMA LIMITED:**

Vaishali Pharma Limited (NSE: VAISHALI), abided by the norms of extending uncompromised quality products, has raised the standards of the Pharmaceutical & Healthcare industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Company's products' quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

In business since 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal &

Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 150+ formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai.

At Vaishali Pharma, we are working tirelessly to make available health improving pharmaceutical products affordable and accessible to all. Looking beyond this immediate term, the upcoming half year shall present more good opportunities for the Company and we shall continue to perform better than the previous half year.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects. One can count upon us for quality pharmaceutical and healthcare products.

**For more details please visit:** [www.vaishalipharma.com](http://www.vaishalipharma.com)

**For any Investor Relations query, please contact:**

<b>Mr. Akshay Jharkhandi</b> <b>Company Secretary</b> Email: <a href="mailto:cs@vaishalipharma.com">cs@vaishalipharma.com</a>	<b>Mr. Ratnesh Singh</b> <b>Chief Financial Officer</b> Email: <a href="mailto:investor@vaishalipharma.com">investor@vaishalipharma.com</a>
---	---

**Note:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.